Pharma Rep Focus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag haemophilia-b

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96

Safety

Safety Pharmaceutical Patients Medicine

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). Hemgenix is the first and only gene therapy approved for haemophilia B. This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).

Patients

Patients Food and Drug Administration Engineering Sales

Can gene therapies for haemophilia defend their high price tags?

CSL doses first patient with haemophilia B gene therapy Hemgenix

Stay Connected